Does rivaroxaban monotherapy improve efficacy and safety compared to combination therapy in patients with atrial fibrillation and stable coronary artery disease?
In patients with atrial fibrillation and stable coronary artery disease, rivaroxaban monotherapy provides noninferior efficacy and superior safety compared to combination therapy.
As antithrombotic therapy, rivaroxaban monotherapy was noninferior to combination therapy for efficacy and superior for safety in patients with atrial fibrillation and stable coronary artery disease. (Funded by the Japan Cardiovascular Research Foundation; AFIRE UMIN Clinical Trials Registry number, UMIN000016612; and ClinicalTrials.gov number, NCT02642419.).
Yasuda et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: